Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
This grant aims to fund mulit-national, multi-diciplinary consortium based projects to investigate combination therapies against cancer. The goal of this call is to fund research projects with high translational relevance with the aim of promoting highly innovative and ambitious collaborative projects in translational cancer research at European and international level. The expected impact of the call is to improve the efficacy of personalized treatment through the development of new combinatorial treatments based on a better understanding of drug mechanistic functions and of their impact on the disease course.
Característiques principals
The grants wants to promet innovative interdiciplinary collaboration and translational research projects based on novel ideas from consolidated previous results. Research proposals should be built on an effective, multidisciplinary and multi-professional collaboration between academic, clinical, epidemiological or public health research teams and industry. Researchers’ exchanges within the consortium are encouraged.
Transcan identifies 3 key reasons to develop combination therapies: to make treatment more effective by targeting several weaknesses together, to reduce side effects of individual drugs, and to reduce the risk of drug resistance emergence.
The expected impact of the call is to improve the efficacy of personalized treatment of cancer patients through the development of new combinatorial treatment strategies, based on a better understanding of drug mechanistic functions and of their impact on the disease course.
Lloc de presentació
IMIM and PSMAR staff who need more information should contact::
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: cbarnwell@researchmar.net Ext.: 1670
Marta López: mlopez4@researchmar.net Ext.: 1576
Convocatòria (URL)
https://ptoutline.eu/app/transcan2024
Informació addicional
Project has the following aims, and proposals need only cover one of these:
  • Aim 1. Development of new tumour derived models to test new drug combination therapies.
  • Aim 2. Design and development of high-throughput drug combination screening platforms to test new combination therapies.
  • Aim 3. Use of immunotherapy and radiotherapy combinations strategies to overcome drug resistance.
    • Requisits
    Call requirement basics are as follows. More information can be found in the attached documentation:
  • Only transnational projects will be funded.
  • Each research consortium must involve a minimum of three (3) and a maximum of six (6) partners (comprising the project coordinator) eligible for funding, coming from at least three (3) different countries whose funders participate in the call.
  • n order to strengthen the European translational cancer research area, a wide inclusion of research teams from all the countries/regions participating in the call is encouraged, therefore the maximum number of partners can be increased up to seven (7) if they include one partner from the following participating countries: Hungary, Latvia, Slovakia and Türkiye.
  • It is mandatory to integrate at least one early-career researcher (ECR) as principal investigator in a consortium and this has to be clearly indicated in the proposal.
    • Dotació
    250,000€ - 450,000€ depending on the role (coordinator or partner) and the number of Spanish beneficiaries
    Durada
    24-36 months

    Arxius

    Arxiu
    TRANSCAN-3_Pre-proposal_application_form_JTC2024.docx
    TRANSCAN-3_Call_Text_JTC2024_Final.pdf
    TRANSCAN-3_Guidelines_for_applicants_JTC2024_Final.pdf